Cat allergy immunotherapy(Circassia Group Plc)

This article is the second part of the consensus. The principle of allergic diseases treatment is "combination of prevention and treatment, four in one":environmental control can avoid or reduce allergens, which is the first choice; allergen vaccine desensitization treatment is a cause-response treatment and has been considered as the first-line treatment; targeting drugs to block allergy or anti-allergy drugs to control symptoms is a commonly used symptomatic treatment method, which needs to be used with reference to the management of chronic diseases; Health education can change patients' misconceptions, improve their initiative and compliance, change their behavior, and improve the efficacy.

Allergen immunotherapy (AIT) is a personalized treatment approach for the allergic airway disease. The most common routes of administration are subcutaneous and sublingual. Local nasal immunotherapy (LNIT) presents another alternative route for allergen desensitization. Nasal mucosa is the first entry site of pathogens and numerous lymphoid organs are located in this area, making LNIT a favorable method for triggering immune tolerance. LNIT has shown promising results in reducing symptoms and medication use in allergic rhinitis patients. Over time, difficulties in dosing adjustments have made this method less popular. Recent advances in intranasal drug delivery systems warrant re-examination of LNIT as a viable option for the treatment of the allergic airway disease.

The scope of the review includes evidences of LNIT in human trials including comparison with placebo and conventional method of immunotherapy. Recent articles regarding the mechanism of LNIT and the challenges of intranasal drug delivery are reviewed. Advances in the LNIT delivery system which have overcome previous limitations demonstrate promising effects.

LNIT presents a judicious alternative for noninjection AIT. The evidences from previous clinical trials and the novel improvement of drug delivery system will lead into the future allergen vaccine production.